Clear Search

Showing 1 result for “Barraclough JY” published 2022.

October 2022

Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis

Diabetes Obes Metab. 2022;24:1927–1938 DOI: 10.1111/dom.14772

A pooled analysis from the CANVAS Program and CREDENCE trial found that canagliflozin did not have a significant effect on the incidence of atrial fibrillation/atrial flutter (AF/AFL) in patients with type 2 diabetes and high risk of cardiovascular disease or chronic kidney disease.

more…